Kumar Neil's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Aug 11, 2025
- Accession no.
- 0000950170-25-106741
- Filed
- Aug 11, 2025
- Trade date
- Aug 7-8, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 8 non-derivative transactions and 0 derivative transactions. Open-market sales total $3.67M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kumar NeilCIK 0001742485 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2025 | Common Stock | SSaleDisposed | −6,784 | $45.09 | −$305,890.56 | 4,751,663 | Indirect | |
| Aug 7, 2025 | Common Stock | SSaleDisposed | −13,216 | $45.64 | −$603,178.24 | 4,738,447 | Indirect | |
| Aug 8, 2025 | Common Stock | SSaleDisposed | −11,795 | $45.88 | −$541,154.6 | 4,726,652 | Indirect | |
| Aug 8, 2025 | Common Stock | SSaleDisposed | −8,205 | $46.71 | −$383,255.55 | 4,718,447 | Indirect | |
| Aug 7, 2025 | Common Stock | SSaleDisposed | −6,784 | $45.09 | −$305,890.56 | 948,902 | Indirect | |
| Aug 7, 2025 | Common Stock | SSaleDisposed | −13,216 | $45.64 | −$603,178.24 | 935,686 | Indirect | |
| Aug 8, 2025 | Common Stock | SSaleDisposed | −11,795 | $45.88 | −$541,154.6 | 923,891 | Indirect | |
| Aug 8, 2025 | Common Stock | SSaleDisposed | −8,205 | $46.71 | −$383,255.55 | 915,686 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.